Safety outcomes of intravenous immunoglobulin (IVIG) in treatment of steroid-refractory immune-checkpoint inhibitor pneumonitis. A phase 1, first-in-human study of DS-2243, an HLA-A*02/NY-ESO–directed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback